TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total weight of milk expressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean score for the PACES scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intensity of joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants With a ≥ 2 mm Reduction From Baseline in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage change in urinary oxalate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Concordance between physician recommendation and patient treatment decision
Endpoint domain: Life impact
Endpoint subdomain: Decision-making
Primary endpoint: Change in SRS-24 Health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Achievement of at least 75% light red granulation tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention Outcome
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: bladder neck descent change after PFMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ano-rectal angle mobility change after PFMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perineal elastography change after PFMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long Chain Polyunsaturated Fatty Acid Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in scores on the Berg Card-Sort Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with standard safety assessments (adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of plasma concentrations of aflibercept, CPT-11 (irinotecan) and Fluorouracil (5-FU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TV Culture Positive Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Kinetics of uptake of [11C]TMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with study drug discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: SUVmax on 68Ga-PSMA PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of TLR-4 polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: expression of TLR-2 and TLR-4 by monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glasgow coma scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: closure of the macular hole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roland Morris Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MTD based on dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Long term death rates
Endpoint domain: Mortality/survival
Primary endpoint: Rate of report opening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of senescent cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sub-population of fibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Pidilizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Achieving Responder Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite number and frequency of treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychometric properties of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the Lu AF11167 plasma concentration-time curve from zero to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of Lu AF11167
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual adherence to Vigabatrin
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SVR at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GVHD rate
Endpoint domain: Adverse events/effects
Primary endpoint: B. infantis levels in infant stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of 123 I-ALTROPANE®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From 0 to t (AUC(0-t)) of a Single Dose Padsevonil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment Emergent Adverse Events During the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Steady state area under the concentration-time curve (AUC(0-12)) of Apixaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe Insertion and Patency of Central Venous Access Catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucagon/insulin (c-peptide) absolute, incremental and area under curve values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: z-score weight-for-age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term effective duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of hospitalization in the Intensive Care Unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Morbidity in the Intensive Care Unit
Endpoint domain: Adverse events/effects
Primary endpoint: Skill decay over time
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: cerebral neurobiological effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Olfactory Changes as Measured by the Smell Identification Test (SIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline (Screening) in Nasal Mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Taste as Measured by a Taste Change Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in thickness of subcutaneous tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of subjects spontaneously reporting severe (Grade 3) adverse events considered associated with the vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing severe (Grade 3) solicited systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Serious adverse events considered associated with the vaccination reported
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Radiographic Response (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urine calcium oxalate supersaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recurrence of catheter-related infection
Endpoint domain: Adverse events/effects
Primary endpoint: Echosonographic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in Percent Hepatic Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: safety and feasibility of stem cell infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: benefit from stem cell infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative index of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of lesions localized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive and negative predictive values of confocal signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of Polymyxin B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain scale (CHIPPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Articular cartilage surface roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Cartilage Oligomeric Matrix Protein (COMP) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in International Knee Documentation Committee (IKDC) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-quit Craving as Assessed by the Questionnaire of Smoking Urges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Withdrawal Symptoms as Assessed by the Wisconsin Smoking Withdrawal Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in MAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid requirements prediction based on BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of JNJ-53718678
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC [0last]) of JNJ-53718678
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-53718678
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative 24-hours total tramadol hydrochloride consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrence of ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High grade dysplasia (HGD) or cancer diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 24 hour EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neutrophil functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal-Child Interactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Snellen Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Symptoms Associated with Band Keratopathy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: brachial artery blood flow via ultrasound doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in duration of diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in total stool volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline In Trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Magnitude of HIV-1 specific serum IgG binding antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response Control and Frustration Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental Trajectory of Brain Anatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Predictors of Adolescent Socio-Emotional Development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Developments of ADHD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time Estimate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effective lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lactic acid change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Creatinine kinase change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival at Day 100, 6 months, and 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Disease-Free Survival at Day 100, 6 months, and 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Absolute change in average step counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in provider-assessed ECOG Performance Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of selected important identified and potential risks
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality, any cause
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of the Diffuse Myocardial Fibrosis Phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immune response enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in PASI 75 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Percentage of patients with clinical difference in DLQI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete Response Rate (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage Change of Sweat Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset and progression of diabetic nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Problem Areas in Diabetes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Used Alcohol From Baseline to 6 Months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Used Marijuana From Baseline to 6 Months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Subjects Reporting Grade 2 or 3 Symptoms (Fever, Vomiting or Diarrhea)
Endpoint domain: Adverse events/effects
Primary endpoint: autonomy level
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Flexibility equivalence of bending methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjustment to illness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of hope
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impact of lymphedema
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean of Last Five 7-point Self Monitored Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Total Scholastic Skills Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean percentage change of Non-HDL Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intraoperative Total Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Remaining Tylenol Tablets With Codeine Not Taken at the End of Day 1 Following Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline Dizziness Handicap Inventory (DHI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Operationally Tolerant Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increased Inspiratory Capacity (IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Touch thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ΔAUCBG 0-2h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClis 0-30min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Achieving Drug-free Diabetes Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalized transection-related blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of Autologous-bone-marrow Injections
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline body weight at 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline satiety responsiveness (satiety quotients) at 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve From Zero to T (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve From Zero to Infinity (AUC Inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve From Zero to Tau (AUC Tau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supraglottic device success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal mucosal gluten-dependent immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of OFDI capsule for diagnosing BE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prolonged length of stay (days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence time
Endpoint domain: Mortality/survival
Primary endpoint: Muscle protein synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-section Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Longitudinal % change in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Device Procedural Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from Baseline HA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of Homeostatic Model Assessment (HOMAR) of Insulin Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in beta cell demand as measured by serum glucose and C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: neonatal hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Negative symptoms assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Door to ECG time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-injection antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportions of patients with documented goals of care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy Root Mean Square (ARMS) Per Data Pair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean systolic and diastolic 24-hour blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Closure of Muscular Ventricular Septal Defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in gut bacterial DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of subjects requiring bail-out anticoagulant therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes